Last reviewed · How we verify
AUR101
AUR101 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
AUR101 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.
At a glance
| Generic name | AUR101 |
|---|---|
| Also known as | No other names |
| Sponsor | Aurigene Discovery Technologies Limited |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BTK is a key component of the B cell receptor signaling complex and plays a crucial role in the development and maintenance of B cell malignancies. Inhibiting BTK has been shown to be effective in treating various B cell cancers.
Approved indications
- Relapsed or refractory mantle cell lymphoma
- Relapsed or refractory marginal zone lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (PHASE2)
- A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AUR101 CI brief — competitive landscape report
- AUR101 updates RSS · CI watch RSS
- Aurigene Discovery Technologies Limited portfolio CI